Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KFRX-04
- Development stage
- Preclinical
- Lead developer
- KeifeRx
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**KFRX-04** is a novel small molecule tyrosine kinase inhibitor (TKI) developed by KeifeRx, optimized for low-dose oral delivery with blood-brain barrier penetration. It acts as a dual inhibitor of **PIKFYVE** (phosphoinositide kinase, FYVE-type zinc finger containing) and **c-Kit** (stem cell growth factor receptor), promoting autophagy to clear toxic proteins and modulating mast cell activity to reduce inflammation. Primarily targeted for mast cell-related disorders, it shows promise in neurodegenerative conditions due to its central nervous system activity.[1][3][5][11]
02
Targets
PIKFYVE (Phosphoinositide kinase, FYVE-type zinc finger containing enzyme)KIT (c-KIT proto-oncogene receptor tyrosine kinase)
Beyond the preview
Go deeper on KFRX-04.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KFRX-04.